General
Preferred name
MECLOFENAMIC ACID
Synonyms
MECLOFENAMATE SODIUM ()
Meclofenamate ()
CL-583.NA SALT ()
Meclofenamic acid sodium ()
Meclomen ()
Meclonax ()
Movens ()
Meclofenamic acid sodium salt monohydrate ()
meclofenamic-acid ()
Meclofenamate (sodium) ()
CB1 antagonist, Bayer ()
Meclofenamic acid (sodium) ()
CI 583 ()
Meclodium ()
CL-583 ()
Meclofenamate sodium anhydrous ()
NSC-757088 ()
Sodium meclofenamate monohydrate ()
Meclofenamate sodium hydrate ()
Sodium meclofenamate ()
INF-4668 ()
INF 4668 ()
NSC-95309 ()
CI-583 ()
Acide meclofenamique ()
Acido meclofenamico ()
Meclofenamate (sodium salt) ()
P&D ID
PD009630
CAS
6385-02-0
644-62-2
67254-91-5
Tags
available
drug candidate
drug
Approved by
FDA
First approval
1980
Drug indication
Obesity
Arthritis
Anti-Inflammatory
Joint pain
Ankylosing spondylitis
Drug Status
approved
vet_approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Meclofenamic acid is a non-steroidal anti-inflammatory drug (NSAID).
(GtoPdb)
DESCRIPTION
Cyclooxygenase and 5-Lipoxygenase inhibitor
(LOPAC library)
DESCRIPTION
Meclofenamic Acid is a non-steroidal anti-inflammatory agent. It has antipyretic and antigranulation activities and is used as a drug used for muscular pain, joint, arthritis and dysmenorrhea. It is a member of the anthranilic acid derivatives class of NSAID drugs. It is also a COX inhibitor and inhibits prostaglandin biosynthesis. It was found to inhibit prostaglandin synthesis and to compete for binding at the prostaglandin receptor site in animal studies. It was found to be an inhibitor of human leukocyte 5-lipoxygenase activity in vitro. It has been listed.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
2
Compound Sets
34
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
JUMP-Target 1 Compound Set
Ki Database
LOPAC library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
80
Molecular Weight
295.02
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
2
Aromatic Ring Count
2
cLogP
4.74
TPSA
49.33
Fraction CSP3
0.07
Chiral centers
0.0
Largest ring
6.0
QED
0.86
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
cyclooxygenase inhibitor
Phospholipase inhibitor
COX inhibitor
cyclooxygenase inhibitor, prostanoid receptor antagonist
Target
Arachidonate 5-lipoxygenase
cyclooxygenase
COX-1
COX-2
ALOX5, CNR1, KCNQ2, KCNQ3, PTGS1, PTGS2
KCNQ2
Endogenous Metabolite
Fat Mass and Obesity-associated Protein (FTO)
Gap Junction Protein
Potassium Channel
COX,FTO
Selectivity
COX / 5-Lipoxygenase
Pathway
Immunology/Inflammation
Neuroscience
cytoskeleton
Membrane Transporter/Ion Channel
Metabolic Enzyme/Protease
Indication
joint pain, muscle pain, rheumatoid arthritis, primary dysmenorrhea (PD)
Disease Area
rheumatology, neurology/psychiatry, endocrinology
Therapeutic Class
Analgesics
Solubility
Soluble in Chloroform (Slightly), Methanol (Slightly, Heated)
Source data
